Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases

CETP Inhibition in CVD Prevention: an Actual Appraisal

(2016) Belinda Di Bartolo et al.   Current Cardiology Reports

New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism

(2015) Katsutoshi Miyosawa et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus

(2015) Marilia C O Sprandel et al.   Cardiovascular Diabetology

PCSK9 inhibitors and cardiovascular disease

(2015) M. John Chapman et al.   CURRENT OPINION IN LIPIDOLOGY

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

(2015) John S. Millar et al.   JOURNAL OF CLINICAL INVESTIGATION

Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9

(2015) Sam J. L. van der Tuin et al.   JOURNAL OF LIPID RESEARCH

Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered1H NMR spectroscopy

(2015) Roger Mallol et al.   JOURNAL OF LIPID RESEARCH

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials

(2015) C. Li et al.   Journal of the American Heart Association

CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism

(2014) Bin Dong et al.   ATHEROSCLEROSIS

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor

(2014) Alexander Tenenbaum et al.   Cardiovascular Diabetology

Residual macrovascular risk in 2013: what have we learned?

(2014) Jean-Charles Fruchart et al.   Cardiovascular Diabetology

Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques

(2014) Thomas P. Roddy et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia

(2012) Marianne Abifadel et al.   ATHEROSCLEROSIS

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

(2012) Liwen Zhang et al.   International Journal of Biological Sciences

Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol

(2011) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease

(2010) Marianne Benn et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM